Yingshi Biotechnology

InnoSience (Yingshi Biotechnology) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and other diseases with high unmet medical needs, particularly those involving the tumor microenvironment and fibrosis. The company's lead program, IN10018, is a highly potent and selective focal adhesion kinase (FAK) inhibitor currently in Phase 2 clinical trials for multiple indications, including platinum-resistant ovarian cancer. InnoSience leverages a robust translational medicine platform to identify synergistic combinations and biomarkers, aiming to overcome drug resistance and improve patient outcomes. Their pipeline includes a diverse range of modalities such as small molecules, monoclonal antibodies, and bispecific antibodies targeting pathways like FGFR and Claudin 18.2. Headquartered in Nanjing, China, with R&D centers in Shanghai and the United States, the company is positioned as a global player in the oncology space.